The Laboratory Monitoring of Altuvoct (Efanesoctocog Alfa): Recommendations From the Laboratory Working Party of the United Kingdom Haemophilia Centres Doctor's Organisation
In the absence of FVIII mimetic therapy, FVIII inhibitors must be assessed using heat-treated patient plasma and a one-stage APTT assay to measure residual FVIII in a Bethesda or Nijmegen-modified Bethesda assay (1B). In the presence of concomitant FVIII-mimetic therapy, FVIII inhibitors must be assessed using heat-treated patient plasma and a chromogenic FVIII assay that uses bovine FX and FIXa substrates to measure residual FVIII in a Bethesda or Nijmegen-modified Bethesda assay (1B).
Authors
- Anne Riddell (ORCID: https://orcid.org/0000-0001-6594-5353)
- Sean Platton (ORCID: https://orcid.org/0000-0002-5466-0448)
- S. B. Williams
- Anna Lowe (ORCID: https://orcid.org/0000-0003-2492-4438)
- Andrew C. Page (ORCID: https://orcid.org/0000-0003-3133-2844)
- Caroline Lawrence (ORCID: https://orcid.org/0009-0005-6871-5920)
- Annette Bowyer (ORCID: https://orcid.org/0000-0003-3425-5848)
- Stephen MacDonald (ORCID: https://orcid.org/0000-0002-4944-3289)
- Jill Martin (ORCID: https://orcid.org/0009-0000-6450-4150)
- Mohammed Khan (ORCID: https://orcid.org/0000-0003-1689-3678)
- JN Sanders
Institutions
- NHS Blood and Transplant (GB)
- Aberdeen Royal Infirmary (GB)
- Glasgow Royal Infirmary (GB)
- Hull Royal Infirmary (GB)
- The Royal Free Hospital (GB)
- Royal London Hospital (GB)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- Edinburgh Royal Infirmary (GB)
- Sheffield Teaching Hospitals NHS Foundation Trust (GB)
- University College London (GB)
- National Institute for Biological Standards and Control (GB)
Publication Details
- Journal
- Haemophilia
- Published
- 2025-11-07
- DOI
- https://doi.org/10.1111/hae.70152
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00